Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL

Michael Y. Choi, MD, Emanuela M. Ghia, PhD, Tanya Siddiqi, MD, William G. Wierda, MD PhD, Hun Ju Lee, Jacqueline C. Barrientos, MD MS, Nicole Lamanna, MD, Alec Goldenberg, Dimitrios Tzachanis, MD PhD, Erin G. Reid, MD MS, Elizabeth K Weihe, MD, Laura Z. Rassenti, PhD, Iris Isufi, MD, Stewart Bieler, BA, Xen Ianopulos, MD PhD, James B. Breitmeyer, MD PhD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD

Blood (2019) 134 (Supplement_1): 1755.

https://doi.org/10.1182/blood-2019-131498

Published: 2019

Journal Articles

Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

Blood (2019) 134 (Supplement_1): 33.

https://doi.org/10.1182/blood-2019-126824

Published: 2019

Journal Articles

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study

Blood (2019) 134 (Supplement_1): 3039.

https://doi.org/10.1182/blood-2019-128706

Published: 2019

Journal Articles

Chronic Lymphocytic Leukemia B Cells Display IgM and IgD Isotype-Restricted Features That Affect Association with Co-Receptors, BCR Signaling, and Leukemic B-Cell Growth In Vivo

Andrea Nicola Mazzarello, PhD, Marcus Dühren-von Minden, PhD, Eva Gentner, BSc, MSc, PhD, Palash Chandra Maity, PhD, Gerardo Ferrer, PhD, Tatyana Tarasenko, Stefano Vergani, PhD, Jacqueline C Barrientos, MD MS, Kanti R Rai, MD, Peter McGuire, Hassan Jumaa, PhD, Nicholas Chiorazzi, MD

Blood (2018) 132 (Supplement 1): 3124.

https://doi.org/10.1182/blood-2018-99-119989

Published: 2018

Journal Articles

Extended Survival in CLL Patients Who Discontinued Idelalisib Because of Colitis Correlates with Higher Th17 Levels in Blood and Colon Tissue

Rukhsana Aslam, MD, Jacqueline C Barrientos, MD MS, Gerardo Ferrer, PhD, Pui Yan Chiu, Kanti R Rai, MD, Nicholas Chiorazzi, MD, Barbara Sherry, PhD

Blood (2018) 132 (Supplement 1): 1848.

https://doi.org/10.1182/blood-2018-99-116910

Published: 2018

Journal Articles

Ibrutinib Treatment Reduces Myeloid Derived Suppressor Cell Numbers and Function in Chronic Lymphocytic Leukemia

Gerardo Ferrer, PhD, Byeongho Jung, BS, Aslam Rukhsana, MD, Pui Yan Chiu, Andrea Nicola Mazzarello, PhD, Florenca Palacios, PhD, Shih-Shih Chen, PhD, Xiao J. Yan, MDPhD, Jacqueline C. Barrientos, MD MS, Jan A. Burger, MD PhD, Jonathan E. Kolitz, MD, Steven L. Allen, MD, Kanti R Rai, MD, Barbara Sherry, PhD, Nicholas Chiorazzi, MD

Blood (2018) 132 (Supplement 1): 239.

https://doi.org/10.1182/blood-2018-99-114799

Published: 2018

Journal Articles

Dual Inhibition of PI3K-δ and PI3K-γ By Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Patient-Derived Xenograft Model

Shih-Shih Chen, PhD, Jeffery Lorne Kutok, MD PhD, Gerardo Ferrer, PhD, Priyadarshini Ravichandran, Michael Ibrahim, Yasmine Kieso, MSCR, Jacqueline C Barrientos, MD MS, David T. Weaver, PhD, Jonathan A Pachter, PhD, Kanti R Rai, MD, Nicholas Chiorazzi, MD

Blood (2018) 132 (Supplement 1): 4420.

https://doi.org/10.1182/blood-2018-99-109853

Published: 2018

Journal Articles

Prognostic Testing and Treatment Approaches in Patients with Chronic Lymphocytic Leukemia: Clinical Experience from an Interim Analysis of the informCLL TM Real-World Registry

Anthony R. Mato, MDMSCE, Jacqueline C. Barrientos, MD MS, Danielle M. Brander, MD, John M. Pagel, MD PhD, Meghan Gutierrez, Karen Kadish, MSN, Brian Tomlinson, MPA, Nilanjan Ghosh, MD PhD, Nick Giafis, PhD, David Ipe, Sandhya Upasani, Murali Sundaram, MBA, PhD, Lucille Ferrante, MD, Carlos Amaya-Chanaga, MD, Reethi Iyengar, PhD, Jeff Sharman, MD

Blood (2018) 132 (Supplement 1): 4425.

https://doi.org/10.1182/blood-2018-99-110566

Published: 2018

Journal Articles

Chronic Lymphocytic Leukemia Treatment Patterns, Dosing, and Sequencing in the Era of Novel Targeted Therapies: Interim Analysis Results from the Prospective informCLL TM Real-World Registry

Jeff Sharman, MD, Jacqueline C. Barrientos, MD MS, Danielle M. Brander, MD, John M. Pagel, MD PhD, Meghan Gutierrez, Karen Kadish, MSN, Brian Tomlinson, MPA, Nilanjan Ghosh, MD PhD, Nick Giafis, PhD, David Ipe, Sandhya Upasani, Murali Sundaram, MBA, PhD, Lucille Ferrante, MD, Carlos Amaya-Chanaga, MD, Reethi Iyengar, PhD, Anthony R. Mato, MD MSCE

Blood (2018) 132 (Supplement 1): 1872.

https://doi.org/10.1182/blood-2018-99-110562

Published: 2018

Journal Articles

Musashi 2 Is Overexpressed in Poor Outcome CLL Patients and Their Proliferative Fraction and Silencing This Gene Induces Apoptosis and Increases Cell Adhesion and Movement

Florencia Palacios, PhD, Xiao-Jie Yan, MD PhD, Gerardo Ferrer, PhD, Jacqueline C Barrientos, MD MS, Jonathan E. Kolitz, MD, Steven L. Allen, Rai Kanti R., MD, Nicholas Chiorazzi, MD

Blood (2018) 132 (Supplement 1): 1837.

https://doi.org/10.1182/blood-2018-99-115060

Published: 2018

NARROW

Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL

Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study

Chronic Lymphocytic Leukemia B Cells Display IgM and IgD Isotype-Restricted Features That Affect Association with Co-Receptors, BCR Signaling, and Leukemic B-Cell Growth In Vivo

Extended Survival in CLL Patients Who Discontinued Idelalisib Because of Colitis Correlates with Higher Th17 Levels in Blood and Colon Tissue

Ibrutinib Treatment Reduces Myeloid Derived Suppressor Cell Numbers and Function in Chronic Lymphocytic Leukemia

Dual Inhibition of PI3K-δ and PI3K-γ By Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Patient-Derived Xenograft Model

Prognostic Testing and Treatment Approaches in Patients with Chronic Lymphocytic Leukemia: Clinical Experience from an Interim Analysis of the informCLL TM Real-World Registry

Chronic Lymphocytic Leukemia Treatment Patterns, Dosing, and Sequencing in the Era of Novel Targeted Therapies: Interim Analysis Results from the Prospective informCLL TM Real-World Registry

Musashi 2 Is Overexpressed in Poor Outcome CLL Patients and Their Proliferative Fraction and Silencing This Gene Induces Apoptosis and Increases Cell Adhesion and Movement

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only